HMI-115
aka - HMI
HMI-115 is a monoclonal antibody and innovative therapeutic candidate under exploration for its potential in combating androgenetic alopecia (AGA). This investigational compound, developed by Hope Medicine, is characterized by its unique mechanism of action which involves targeting the prolactin receptor.
Dysregulated prolactin signaling, traditionally associated with lactation, plays a significant role in hair loss mechanisms, particularly in androgenetic alopecia. Prolactin receptors, present in hair follicles, mediate effects that may shorten the hair growth cycle, enhance inflammatory responses, contribute to follicular fibrosis, and directly diminish hair shaft integrity.
The significance of HMI-115 in the realm of alopecia treatment lies in its pioneering approach. AGA, driven by a combination of hormonal and genetic factors leading to hair thinning and loss, has limited treatment options that directly confront these underlying causes. HMI-115's mechanism, by potentially altering the hormonal influence on hair follicles, offers a targeted solution that could halt or even reverse the hair loss process.
Ongoing research into HMI-115, including early-stage clinical trials, seeks to unveil its efficacy and safety profile. While specifics of these studies are highly anticipated, preliminary partnerships, such as the collaboration between Chime Biologics and Hope Medicine, aim to accelerate the development and potential market launch of HMI-115. In 2021, HMI-115 received the US FDA Clearance of IND Application for Phase II clinical trial for the treatment of endometriosis.
Within the community, the reception to HMI-115 is characterized by cautious optimism mingled with keen interest. The unique action of targeting the prolactin receptor as a method to counteract hair loss has sparked hope among individuals suffering from AGA. This enthusiasm is tempered by the understanding that the path from investigational drug to approved treatment is long and fraught with regulatory and scientific hurdles.
While it's still early days for HMI-115, the ongoing research and development efforts highlight the potential for this compound to become a pivotal solution for those grappling with AGA. The hope is that HMI-115 will fulfill its potential as an effective and safe option for managing hair loss.
Research
20 / 50 resultsresearch The State-of-the-Art in the Management of Androgenetic Alopecia: A Review of New Therapies and Treatment Algorithms
research Recent Approaches of Antibody Therapeutics in Androgenetic Alopecia
research Recent Advances in Drug Development for Hair Loss
research Topical Application of the Wnt/β-Catenin Activator Methyl Vanillate Increases Hair Count and Hair Mass Index in Women with Androgenetic Alopecia
research A Dietary Supplement Improves Age-Related Dermatological Changes: Observational, Anecdotal, Spontaneous Study
research Effects of a New Topical Treatment Containing Several Hair Growth Promoters in Women with Early Female Pattern Hair Loss
research Hypotensive Activity and Toxicology of Constituents from Bombax Ceiba Stem Bark
research A Segmental Approach to Scoring Hair Density from Global Images: Introducing the Scalp Coverage Scoring Method for Clinical Trials and Practice
research The Pathophysiology of Polycystic Ovary Syndrome: Understanding PCOS and Its Endocrinology
research Androgens in SARS-CoV-2 Coronavirus Infections
research Dermal EZH2 Simultaneously Orchestrates Wnt/β-Catenin Signaling Dependent Dermal Differentiation and Retinoic Acid Signaling Dependent Epidermal Proliferation During Murine Skin Development
research Dermal EZH2 Simultaneously Orchestrates Dermal Differentiation and Epidermal Proliferation During Murine Skin Development
research Efficacy of a Cosmetic Product Mimicking PRP in Androgenetic Alopecia
research An Open-Label Evaluator Blinded Study of the Efficacy and Safety of a New Nutritional Supplement in Androgenetic Alopecia: A Pilot Study
research Musculoskeletal and Body Composition Response to High-Dose Testosterone with Finasteride After Chronic Incomplete Spinal Cord Injury: A Randomized, Double-Blind, and Placebo-Controlled Pilot Study
research A Study on the Effectiveness and Safety of Herbal Extract Combination Compared to 3% Minoxidil Solution for the Treatment of Androgenetic Alopecia: A Randomized, Double-Blind, Controlled Trial
research Exhaustive Analysis of Scalp Hair Regression: Subjective and Objective Perception from Initial Hair Loss to Severe Miniaturization and Drug-Induced Regrowth
